aTyr Pharma

About:

aTyr Pharma is a biotherapeutics company that discovers and develops protein biologics for human therapeutics.

Website: http://www.atyrpharma.com

Twitter/X: aTyrNews

Top Investors: Deerfield, Sofinnova Investments, Polaris Partners, T. Rowe Price, Viking Global Investors

Description:

aTyr Pharma is a biotherapeutics company that discovers and develops protein biologics for human therapeutics. The company has established a dominant intellectual property estate surrounding Physiocrine-based compositions and potential therapeutic applications. aTyr’s key programs are focused on immunomodulation disorders in the areas of inflammation and immunity and are in preclinical development. The company's primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases. The privately held biotech was founded by The Scripps Research Institute Professor Paul Schimmel, a leading aminoacyl tRNA synthetase scientist, and is backed by top life sciences investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Ventures.